Novo Holdings A/S’s VYNE Therapeutics VYNE Stock Holding History

Novo Holdings A/S’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-353	Closed	-$5.23M	–	24
2018 Q4	$5.23M	Sell	353 -46	-12%	-$1.03M	0.74%	19
2018 Q3	$14.1M	Hold	399	–	–	1.12%	14
2018 Q2	$11.7M	Buy	399 +21	+6%	+$816K	1.17%	12
2018 Q1	$51.2M	Buy	+378	New	+$46M	6.42%	3

Other funds holding VYNE

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Novo Holdings A/S's VYNE Position: Q1 2019 in Review

Novo Holdings A/S sold out of VYNE Therapeutics (VYNE) in Q1 2019, closing a stake of 353 shares — an estimated $5.23M sold.

Novo Holdings A/S first reported a position in VYNE in Q1 2018 and held it in 4 quarters. The position peaked at $51.2M in Q1 2018. 53 funds tracked by Wall St. Rank hold VYNE as of Q1 2019.

Novo Holdings A/S reported no remaining VYNE Therapeutics position as of Q1 2019 after selling out during the quarter.
Novo Holdings A/S sold 353 VYNE Therapeutics shares in Q1 2019, an estimated $5.23M.
Novo Holdings A/S first reported a position in VYNE Therapeutics in Q1 2018 and held it in 4 quarters.
Novo Holdings A/S's VYNE Therapeutics position peaked at $51.2M in Q1 2018.
53 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2019.

Based on Novo Holdings A/S's 13F filing for Q1 2019, filed 15 May 2019.